REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
01/06/2026
Voltar para busca
Dado oficial do USPTO
LYMPHOQUANT
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
LYMPHOQUANT
ST13
US500000087588377Classe
1, 5, 42, 44
Pedido
87588377
Registro
6373233
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
48
Atualização mais recente
02/06/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5, 42, 44
Data de depósito
29/08/2017
Data de registro
01/06/2021
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
01/06/2021
Última transação
02/06/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
08/09/2019
Primeiro uso no comércio
08/09/2019
Código do desenho
4
Tipo de titular
03
Localização do titular
SAN DIEGO, CA, US
Examinador
CLARK, ROBERT C
Unidade examinadora
L10
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
INVIVOSCRIBE, INC.
Invivoscribe Technologies, Inc.
Representantes
Sarah W. Matthews Dentons Durham Jones Pinegar
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Reagents for scientific and research usebuffer solutionsenzymesmolecular probesDNA and RNA polymerasesnucleic acidsnucleic acid derivativesprimers for use in PCRDNA templatesRNA templatesdyes and biotechnology reagents and solvents for sample preparationpurificationlysismodification and manipulation of cells; diagnostic reagent kits for scientific and research use comprised of buffer solutionsenzymesmolecular probesDNA and RNA polymerasesnucleic acidsnucleic acid derivativesprimers for use in PCRDNA templatesRNA templatesdyes and biotechnology reagents and solvents for sample preparationpurificationlysismodification and manipulation of cells; diagnostic reagent kits for scientific and research use comprised of chemical and biological reagents for non-medical purposes; diagnostic reagents for scientific and research use; diagnostic assays for researchclinical researchlaboratory research use
Classe 5
Assays for the treatment or diagnosis of disease; medical diagnostic reagentsbuffer solutionsenzymesmolecular probesDNA and RNA polymerasesnucleic acidsnucleic acid derivativesprimers for use in PCRDNA templatesRNA templatesdyes and biotechnology reagents and solvents for sample preparationpurificationlysismodification and manipulation of cells; medical diagnostic kits comprised of buffer solutionsenzymesmolecular probesDNA and RNA polymerasesnucleic acidsnucleic acid derivativesprimers for use in PCRDNA templatesRNA templatesdyes and biotechnology reagents and solvents for sample preparationpurificationlysismodification and manipulation of cells; medical diagnostic reagent kits comprised of chemical and biological reagents for the treatmentmonitoring and diagnosis of disease; medical diagnostic reagent kits comprised of medical reagents for clinical or medical use; medical diagnostic assays for the treatment and diagnosis of disease; medical diagnostic assays for testing of bodily fluids
Classe 42
DNA analysis services for scientific research purposesDNA sequencingbioinformatics analysisinterpretation of biological DNA data generated from reagents and assays
Classe 44
DNA screening for medical purposesDNA sequencingbioinformatics analysisinterpretation of biological DNA data generated from reagents and assays
Publicações
Histórico de despachos e eventos da marca no USPTO.
48 publicações encontradas
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
10/10/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
10/10/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
10/10/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
01/06/2021
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
28/04/2021
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
27/04/2021
SUPC
STATEMENT OF USE PROCESSING COMPLETE
26/04/2021
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
26/04/2021
IUAF
USE AMENDMENT FILED
25/03/2021
EISU
TEAS STATEMENT OF USE RECEIVED
25/03/2021
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
02/10/2020
EX5G
SOU EXTENSION 5 GRANTED
01/10/2020
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
30/09/2020
EXT5
SOU EXTENSION 5 FILED
24/09/2020
EEXT
SOU TEAS EXTENSION RECEIVED
24/09/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
27/03/2020
EX4G
SOU EXTENSION 4 GRANTED
25/03/2020
EXT4
SOU EXTENSION 4 FILED
25/03/2020
EEXT
SOU TEAS EXTENSION RECEIVED
25/03/2020
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
28/09/2019
EX3G
SOU EXTENSION 3 GRANTED
26/09/2019
EXT3
SOU EXTENSION 3 FILED
26/09/2019
EEXT
SOU TEAS EXTENSION RECEIVED
26/09/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
23/03/2019
EX2G
SOU EXTENSION 2 GRANTED
21/03/2019
EXT2
SOU EXTENSION 2 FILED
21/03/2019
EEXT
SOU TEAS EXTENSION RECEIVED
21/03/2019
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
29/09/2018
EX1G
SOU EXTENSION 1 GRANTED
27/09/2018
EXT1
SOU EXTENSION 1 FILED
27/09/2018
EEXT
SOU TEAS EXTENSION RECEIVED
27/09/2018
ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
05/09/2018
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
28/03/2018
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
28/03/2018
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
27/03/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
30/01/2018
PUBO
PUBLISHED FOR OPPOSITION
30/01/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
10/01/2018
ALIE
ASSIGNED TO LIE
26/12/2017
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/12/2017
XAEC
EXAMINER'S AMENDMENT ENTERED
05/12/2017
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
05/12/2017
GNEA
EXAMINERS AMENDMENT E-MAILED
05/12/2017
CNEA
EXAMINERS AMENDMENT -WRITTEN
05/12/2017
DOCK
ASSIGNED TO EXAMINER
04/12/2017
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/09/2017
NWAP
NEW APPLICATION ENTERED
01/09/2017
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace LYMPHOQUANT ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.